Shanghai Yizhong Pharmaceutical (688091.SH): First dosing of the first dose cohort completed in Phase I clinical trial of innovative drug YXC-001

Shanghai Yizhong Pharmaceutical (688091.SH) announced that the first dosing of the first dose cohort in the Phase I clinical trial of its self-developed innovative drug YXC-001 (a trifunctional antibody fusion protein) has recently been completed by its wholly-owned subsidiary Shanghai Youxicuang Pharmaceutical Technology Co., Ltd. Addressing the pain point that existing single-target drugs struggle to balance efficacy and toxicity, the company, based on its exclusive multifunctional antibody R&D platform, has prospectively laid out YXC-001, a globally leading next-generation Class 1 anti-tumor innovative drug. As a First-in-Class trifunctional antibody fusion protein with a unique structure, YXC-001 precisely integrates a PD-1 antibody (pembrolizumab), an anti-VEGF antibody (bevacizumab), and an optimized low-toxicity IL-2 (aldesleukin), achieving mechanistic innovation while potentially breaking through the existing limitations of late-stage solid tumor treatment. Preclinical pharmacodynamic studies showed that in a mouse lung cancer model, YXC-001 at the same dose demonstrated significantly superior efficacy compared with the control drug PD-1 monoclonal antibody (Keytruda) and the control drug PD-1/VEGF bispecific antibody drug, and exhibited an excellent dose-response relationship.